Provided is a pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability. Said pharmaceutical comprises a combination of: an anti-VEGF agent； and a hydantoin derivative or a pharmacologically permitted salt thereof, said hydantoin derivative being represented by general formula (I) (in which X represents a halogen atom or a hydrogen atom, and R and R each independently represent a hydrogen atom or a C alkyl group that may be substituted).
